Sökning: onr:"swepub:oai:DiVA.org:uu-327250" >
An Intraprostatic M...
An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer
-
- Tammela, T L (författare)
- Tampere Univ Hosp, Dept Urol, Tampere, Finland.; Univ Tampere, Tampere, Finland,Department of Urology, Tampere University Hospital and University of Tampere, Tampere, Finland
-
- Häggman, Michael (författare)
- Uppsala universitet,Urologkirurgi,Department of Urology, Uppsala University Hospital, Uppsala, Sweden
-
- Ladjevardi, Sam (författare)
- Uppsala universitet,Urologkirurgi,Department of Urology, Uppsala University Hospital, Uppsala, Sweden
-
visa fler...
-
- Taari, K (författare)
- Helsinki Univ Hosp, Helsinki, Finland,Department of Urology, Helsinki University Hospital, Helsinki, Finland
-
- Isotalo, T (författare)
- Paijiat Hame Cent Hosp, Lahti, Finland,Department of Urology, Päijät-Häme Central Hospital, Lahti, Finland
-
- Lennernäs, Hans (författare)
- Uppsala universitet,Institutionen för farmaci,Department of Pharmacy, Uppsala University, Uppsala, Sweden
-
- Weis, Jan, 1956- (författare)
- Uppsala universitet,Radiologi,Radiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
-
- von Below, Catrin, 1970- (författare)
- Uppsala universitet,Radiologi,Radiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
-
- Wassberg, Cecilia (författare)
- Uppsala universitet,Radiologi,Radiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
-
- Lennernäs, Bo, 1963- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Oncology, Örebro University Hospital, Örebro, Sweden,Univ Orebro, Dept Oncol, Orebro, Sweden
-
- Tolf, Anna (författare)
- Uppsala universitet,Klinisk och experimentell patologi,Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden
-
- Axén, N (författare)
- LIDDS AB, Uppsala, Sweden
-
- Gölander, C-G (författare)
- LIDDS AB, Uppsala, Sweden
-
- Ahlström, Håkan, 1953- (författare)
- Uppsala universitet,Radiologi,Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden
-
visa färre...
-
Tampere Univ Hosp, Dept Urol, Tampere, Finland; Univ Tampere, Tampere, Finland Department of Urology, Tampere University Hospital and University of Tampere, Tampere, Finland (creator_code:org_t)
- Ovid Technologies (Wolters Kluwer Health), 2017
- 2017
- Engelska.
-
Ingår i: Journal of Urology. - : Ovid Technologies (Wolters Kluwer Health). - 0022-5347 .- 1527-3792. ; 198:6, s. 1333-1339
- Relaterad länk:
-
https://helda.helsin...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- PURPOSE: To investigate tolerability, safety and antitumor effects of a novel intra-prostatic depot formulation of antiandrogen 2-hydroxyflutamide (2-HOF in NanoZolid(®)) in men with localized prostate cancer (PCa).MATERIALS AND METHODS: Two clinical trials, LPC-002 and LPC-003, were conducted on a total of 47 men. The formulation was injected transrectally into the prostate with ultrasound guidance. In LPC-002 the effects on prostate specific antigen (PSA) and prostate volume (PV) were measured over 6 months on 24 patients. In LPC-003, antitumor effects were evaluated with histopathology, magnetic resonance imaging (MRI) including spectroscopy (MRS) during 6 or 8 weeks on 23 patients. In both studies, testosterone and 2-HOF in plasma were measured, as well as quality-of-life parameters.RESULTS: In LPC-002 (mean dose 690 mg) a reduction in PSA and PV was observed. The nadir values for PSA and PV were on average 24.9 % and 14.0 % below baseline, respectively. When increasing the dose in LPC-003 (920 mg and 1740 mg), the average PSA dropped 16 % and 23 %, respectively, after 6 and 8 weeks. MRI/MRS showed morphological changes and a global drop in metabolite concentrations following treatment indicating an antitumor response. The injections did not result in hormone related side effects. In total, three serious adverse events were reported, all resolved by oral antibiotic treatment.CONCLUSIONS: The intraprostatic injections of 2-HOF depot formulations indicated anti-tumor effects and proved safe and tolerable. However, for better anti-cancer effects higher doses and better dose distribution are suggested.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- NanoZolid
- Prostate cancer
- bioresorbable
- calcium sulphate
- local treatment
- modified-release
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Tammela, T L
-
Häggman, Michael
-
Ladjevardi, Sam
-
Taari, K
-
Isotalo, T
-
Lennernäs, Hans
-
visa fler...
-
Weis, Jan, 1956-
-
von Below, Catri ...
-
Wassberg, Cecili ...
-
Lennernäs, Bo, 1 ...
-
Tolf, Anna
-
Axén, N
-
Gölander, C-G
-
Ahlström, Håkan, ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Journal of Urolo ...
- Av lärosätet
-
Uppsala universitet
-
Örebro universitet